Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;1(4):421-30.

Cyclosporin-A associated malignancy

Jonathan M Durnian  1 , Rosalind M K Stewart, Richard Tatham, Mark Batterbury, Stephen B Kaye
Affiliations
Free PMC article

Cyclosporin-A associated malignancy

Jonathan M Durnian et al. Clin Ophthalmol. 2007 Dec.
Free PMC article

Abstract

The use of cyclosporin is well established within the ophthalmology community, especially against sight threatening intraocular inflammation. It is well known however, that immunosuppression in general is a risk factor for the development of malignancy and numerous studies point to the risk imposed by cyclosporin. This article analyses and reviews all relevant studies with regard to the development of malignancy associated with the use of cyclosporin and extrapolates this into the ophthalmic setting. This is to enable clinicians to assess the risks in individual patients and to present a monitoring regime which can be used in patients undergoing cyclosporin treatment. The review is solely concerned with the risk of the development of malignancy following cyclosporin immunosuppression and not with any other adverse effect.

Keywords: ciclosporine; cyclosporin; cyclosporine; malignancy; neoplasm and cancer development.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahlers C, Kreideweiss S, Nordheim A, et al. Cyclosporin A inhibits Ca2+ mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells. Eur J Biochem. 1999;264:952–9. - PubMed
    1. Algros MP, Angonin R, Delbosc B, et al. Danger of systemic cyclosporin for corneal graft. Cornea. 2002;21:613–14. - PubMed
    1. Amato MP, Pracucci G, Ponziani G, et al. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology. 1993;43:831–3. - PubMed
    1. Andre N, Roqueelaure B, Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses. 2004;63:647–52. - PubMed
    1. Arellano F, Krupp P. Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Br J Rheumatol. 1993;32(Suppl 1):72–5. - PubMed

LinkOut - more resources